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Summary The expression of a novel tumour associated antigen CA 242, defined by the monoclonal antibody
C 242, was studied by immunoperoxidase staining in formalin-fixed, paraffin-embedded tissue sections from
normal pancreata, pancreata with pancreatitis and benign and malignant pancreatic neoplasms. The antigenic
determinant of the C 242 antibody is a sialylated carbohydrate structure, related but chemically different from
tumour marker antigens CA 19-9 and CA 50. Thirty-eight of 41 (93%) well to moderately differentiated ductal
adenocarcinomas of the pancreas and all cystadenocarcinomas were positive for CA 242. The staining was
most intense in the apical border of the cells, and in the intraluminal mucus. Only two out of seven poorly
differentiated adenocarcinomas stained, and the number of positive cells was smaller than in well differentiated
carcinomas. Only occasional cells were stained in one out of five anaplastic carcinomas. Part of large ducts
were positive in 91% (21/23) specimens of chronic pancreatitis. In acute pancreatitis small terminal ducts,
centro-acinar cells and some large ducts stained for CA 242. In normal pancreas only a few small terminal
ducts were CA 242 positive. Carcinomas always stained more strongly for CA 242 than normal pancreatic
tissue adjacent to the carcinoma. The results of CA 242 are compared with those of tumour marker antigens
CA 50 and CA 19-9. Serum CA 242 levels were determined in 23 of the patients with pancreatic cancer using a
fluoroimmunoassay. Fifteen (65%) patients had an elevated value. There was no clear-cut correlation between
the serum levels and the immunohistochemical expression of the CA 242 antigen. The expression of CA 242 in
pancreatic tissue resembles that of CA 50 and is similar to CA 19-9. The antigen is expressed in serum of many
patients with pancreatic cancer and, therefore, is a potential candidate for a serum tumour marker.
Monoclonal antibody C 242 was obtained after immunisation
of mice with a human colorectal adenocarcinoma cell line
COLO 205 (Lindholm et al., 1985). The structure of the
antigenic determinant of CA 242 is not completely defined,
but it seems to be a sialylated carbohydrate structure related
to type I chain (O. Nilsson, personal communication). It is
related, although not identical, to the antigenic determinants
of tumour markers CA 19-9, defined by antibody
1116 NS 19-9 (19-9 antibody) (Koprowski et al., 1979), and
CA 50, defined by antibody C 50 (Lindholm et al., 1983),
raised against the same carcinoma cell line as the C 242
antibody. The C 50 antibody reacts with sialosylfucosyllac-
totetraose (Mansson et al., 1985), corresponding to sialylated
blood group antigen Lewisa, which is the antigenic deter-
minant detected also by the 19-9 antibody (Koprowski et al.,
1979; Magnani et al., 1982). In addition, the C 50 antibody
reacts with at least one other carbohydrate structure, sialosyl-
lactotetraose (Nilsson et al., 1985).
It has been proposed that CA 242 appears in serum on the
same macromolecule as CA 50 and CA 19-9 (Lindholm et al.,
1985). Recently a DELFIA assay for quantitation of CA 242
in serum has been described (Nilsson et al., 1988).
Previously we have reported the immunohistochemical exp-
ression of the CA 19-9 and CA 50 antigens in pancreatic
tumours, in normal pancreatic tissue and in pancreatitis
(Haglund et al., 1986a, b). We have now studied the expres-
sion of the CA 242 antigen in pancreatic lesions by
immunoperoxidase staining. Similarities with and differences
from the expression of CA 19-9 and CA 50 are discussed.
Material and methods
Specimens
Specimens studied were the following: 20 samples of normal
pancreatic tissue (15 of which were resection surfaces from
pancreata with cancer or chronic pancreatitis); 10 acute and
11 chronic pancreatitis tissue samples; 48 ductal adenocar-
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cinomas (38 primary tumours and 10 metastatic tumours);
five anaplastic carcinomas, seven cystadenomas, three cyst-
adenocarcinomas and nine neoplasms of endocrine origin.
The samples were formalin-fixed, paraffin-embedded surgical
specimens, which had been stored for between 6 months and
10 years.
Antibodies
Tissue culture supernatant containing mouse monoclonal
antibody C 242 (IgGi) (Lindholm et al., 1985) was used for
the CA 242 stainings. The optimal dilutions of primary
antibodies were determined in control series.
Stainingprocedure
Paraffin sections 5 jm thick were deparaffinised and treated
with 0.4% pepsin (2,500 FIP-U g-'; Merck, Darmstadt,
FRG) in 0.01 N HCI for 1 h at 37°C. All sections were then
incubated in 0.5% hydrogen peroxide in methanol for 30 min
to block endogenous peroxidase, incubated with non-immune
horse serum, diluted 1: 20, and then reacted with the C 242
antibody, diluted 1: 50. Bound antibody was visualised by
the avidin-biotin complex assay (ABC; Vectastain, Vector,
Burlingame, CA). The sections were successively treated with
biotinylated anti-mouse immunoglobulin antiserum, avidin
and biotinylated horseradish peroxidase complex. Each step
was followed by washing in phosphate-buffered saline (PBS).
Finally, sections were incubated with 3-amino-9-ethyl-
carbazole (AEC) and hydrogen peroxide, and then counter-
stained with haematoxylin. Sections stained with non-
immune mouse serum and PBS, respectively, instead of the
primary antibody served as negative controls.
The effect of enzyme pretreatment was tested in a series
where CA 242 positive sections were pretreated, with 0.4%
pepsin in 0.01 N HCI, with 0.01 N HCI only or with PBS.
The optimal staining reaction was obtained after pepsin
treatment for 1 h. None of the negative specimens became
positive after pepsin treatment.
An arbitrary scoring of distribution using + or + + was
used. Specimens including both carcinoma and normal panc-
reatic tissue were used for comparisons between staining
intensity of cancerous and normal tissue.
Br. J. Cancer (I989), 60, 845 851 '." The Macmillan Press Ltd., 1989846 C. HAGLUND et al.
Neuraminidase treatment
In a control series, sections were incubated with 0.03, 0.1 and
0.3 U ml-' Vibrio cholerae neuraminidase (1 U ml-') (Behr-
ingwerke, Marburg, FRG), diluted with PBS containing
0.9 mM Ca2+ and 0.5mMMg2+ for 2 h at 37°C to remove
sialic acid before incubation with the C 242 antibody. Sec-
tions incubated with buffer instead of neuraminidase and
sections incubated with neuraminidase and then stained for
CA 19-9 served as controls.
Serum assay
Serum CA 242 levels were measured by a dissociation-
enhanced lanthidine fluoroimmunoassay (DELFIA; Phar-
macia Diagnostics, Uppsala, Sweden). Briefly, aliquots of
patient sera were incubated for 2 h at 20°C in microwells
coated with purified mouse monoclonal antibodies against
the CA 50 antigen. After washes the wells were treated for
1 h with purified anti-CA 242 monoclonal antibodies com-
plexed with europium chelate (Pharmacia). The bound
europium was finally quantitated after washings by adding
commercial scintillation solution (LKB/Wallac, Turku, Fin-
land) and by counting the wells in a 1230 Arcus Fluorometer
(LKB/Wallac). An upper limit of normal of 20 U ml ', based
on serum levels of healthy blood donors, was used for the
assay (Nilsson et al., 1988).
Results
Normalpancreas
In normal pancreas 17 out of 20 specimens (85%) stained for
CA 242 (Figure la). A positive reaction was typically seen in
the apical border of some ductal cells. Large ducts were more
often positive and stained more strongly than small ducts.
Normal pancreatic tissue adjacent to chronic pancreatitis or
carcinoma showed the same staining pattern and intensity.
Acinar cells and Langerhans' islets were consistently
negative.
Pancreatitis
All but one specimen of chronic pancreatitis (91%) were
positive for CA 242 (Figure 2). The antigen was expressed
mainly in the apical border of ductal cells, but also to some
extent intracellularly. The staining intensity was much
stronger than in normal pancreatic ducts. Intraluminal mucus
stained positively. Chronic pancreatitis was also seen in car-
cinoma specimens adjacent to the tumour. The staining pat-
tern was similar to that of specimens with chronic panc-
reatitis only. All sections of acute pancreatitis stained for
CA 242. The staining was intense and widely distributed in
small terminal ducts and centro-acinar cells, whereas only
some of the large ducts were positive for CA 242 (Figure 3).
Thus, in most cases, the staining pattern clearly differed from
that seen in chronic pancreatitis and in normal pancreata, in
which centroacinar cells were negative. Acinar structures and
Langerhans' islets were always negative for CA 242.
Well to moderately differentiated adenocarcinomas
Thirty-eight out of 41 (93%) tumours expressed CA 242
(Figure 4). Frequently, the staining was focal. In well
differentiated areas, the antigen was predominantly seen in
the brush border and in the mucus, which stained intensely.
The staining was more diffuse and mainly intracytoplasmic in
moderately differentiated areas. In many specimens with
intense staining, the surrounding matrix was diffusely
positive. In all cases the staining intensity of the carcinoma
was stronger than that of adjacent pancreatic tissue. All eight
specimens from metastases were positive and had the same
staining pattern as primary tumours. No differences between
Figure 1 Normal pancreas. Immunoperoxidase staining with the
C 242 antibody (a), the 1116 NS 19-9 antibody (b) and the C 50
antibody (c), counterstained with haematoxylin. Bar = 1I00 tm.
Positivity for CA 242, CA 19-9 and CA 50 was seen in some
ductal cells (large arrow). Centro-acinar cells also stained for
CA 50 (small arrow).CA 242 IN PANCREATIC LESIONS 847
Figure 2 Chronic pancreatitis. Immunoperoxidase staining with the C 242 antibody, counterstained with haematoxylin.
Bar = 100tm. Positivity for CA 242 is seen in ductal cells.
Figure 3 Acute pancreatitis. Immunoperoxidase staining with the C 242
Bar = 100lgm. Small terminal ducts and centro-acinar cells stain for CA 242.
antibody, counterstained with haematoxylin.
Figure 4 Well differentiated ductal adenocarcinoma of the pancreas. Immunoperoxidase staining with the C 242 antibody,
counterstained with haematoxylin. Bar= 100pm. Malignant epithelial cells and intraluminal mucus stain intensely for CA 242.848 C. HAGLUND et al.
CA 242 positive and negative carcinoma specimens could be
seen using conventional histochemistry.
Poorly differentiated and anaplastic carcinomas
The expression of CA 242 was rather similar in poorly
differentiated and anaplastic carcinomas. Two out of seven
poorly differentiated adenocarcinomas and one of five ana-
plastic carcinomas expressed the antigen. In poorly
differentiated adenocarcinomas the staining was intracyto-
plasmic, and the number of positive cells was smaller than in
well differentiated carcinomas, and in anaplastic carcinomas
cells were stained only occasionally (Figure 5). One of three
metastases was positive.
Cystic tumours
All four mucinous cystadenomas and three cystadenocar-
cinomas were positive for CA 242 (Figures 6 and 7).
Predominantly the apical parts of the epithelial cells and the
mucus were stained, but particularly in cystadenocarcinomas
intracytoplasmic staining was also seen in many cells. The
staining pattern was the same as in the ductal adenocar-
cinomas, but more intense. Three serous cystadenomas were
negative for CA 242.
Islet cell tumours
Five benign islet cell tumours were negative for CA 50,
whereas in two of four islet cell carcinomas, the cytoplasm of
a few cells stained (Figure 8).
Sensitivity to treatment with neuraminidase
Incubation of carcinoma specimens with 0.03 U ml-'
neuraminidase slightly weakened the staining intensity,
whereas 0.1 and 0.3 U ml' totally abolished the CA 242
staining. In the control series the CA 19-9 staining was
abolished by 0.3 U ml' neuraminidase.
Comparison ofCA 242 with CA 19-9 and CA 50
The staining pattern of CA 242 very much resembled that of
CA 19-9, whereas a clear difference was seen between the
expression of CA 242 and CA 50. In normal pancreas only
some of the small ducts were positive for CA 242, whereas
the CA 50 staining was uniformly distributed in small ducts
and centro-acinar cells (Figure la-c). There was a similar
difference in chronic pancreatitis. In acute pancreatitis the
distribution of centro-acinar cells positive for CA 50 was
uniform, whereas the staining pattern for CA 242 was more
Figure 5 Anaplastic carcinoma of the pancreas. Immunoperoxidase staining with the C 242 antibody, counterstained with
haematoxylin. Bar= 100 gm. Occasional carcinoma cells stain for CA 242 (arrows).
Figure 6 Mucinous cystadenoma of the pancreas. Immunoperoxidase staining with the C 242 antibody, counterstained with
haematoxylin. Bar = 100 gim. Predominantly apical parts but also intracytoplasmic structures of mucinous epithelial cells stain for
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patchy. In carcinomas and cystadenocarcinomas the same
structures stained for CA 242, CA 50 and CA 19-9. However,
the intensity of the CA 242 and CA 19-9 staining was
stronger and more widely distributed in most specimens than
that of CA 50. Carcinomas stained more strongly for
CA 242, as for CA 19-9, than pancreatic tissue adjacent to
the tumour, whereas the opposite was the case for CA 50.
Most specimens, 74 out of 113, were positive for all three
antigens, whereas seven specimens were negative for all
(Table I). All specimens of normal pancreas, as well as acute
and chronic pancreatitis, stained for CA 50. One specimen of
normal pancreas was negative for CA 242, three specimens
for CA 19-9 and two specimens for both CA 242 and
CA 19-9. One specimen of acute pancreatitis was negative for
Figure 7 Cystadenocarcinoma of the pancreas. Immunoperoxidase staining with the C 242 antibody, counterstained with
haematoxylin. Bar = 100 jsm. The cystadenocarcinoma epithelium stains intensely for CA 242.
Figure 8 Islet cell carcinoma. Immunoperoxidase staining
Bar = 100gm. A few cells stain for CA 242 (arrow).
with the C 242 antibody, counterstained with haematoxylin.
Table I Comparison of the immunohistochemical expression of CA 242, CA 50 and CA 19-9 in benign and malignant pancreatic lesions
Number ofspecimens
CA 242 + CA 242 + CA 242 + CA 242 + CA 242- CA 242- CA 242- CA 242-
CA 50 + CA 50 + CA 50- CA 50- CA 50 + CA 50 + CA SO- CA 50-
Specimens Total CA 19-9 + CA 19-9 - CA 19-9 + CA 19-9 - CA 19-9 + CA 19-9 - CA 19-9 + CA 19-9 -
Normal pancreas 20 14 3 - - 1 2
Acute pancreatitis 10 9 1 - -
Chronic pancreatitis 11 10 - - I
Well differentiated adenocarcinoma 41 31 5 2 1 1 1
Poorly differentiated and anaplastic
carcinoma 12 3 - - 3 3 1 2
Cystic tumours
serous 3 - - - - 3
mucinous 4 4
Islet cell tumours 3 3
benign 5 - - - - - - 5
malignant 4 - 2 -2 - -
Total 113 74 1 1 2 5 12 2 7850 C. HAGLUND et al.
CA 19-9, and one specimen of chronic pancreatitis for both
CA 19-9 and CA 242. Five well to moderately differentiated
ductal adenocarcinomas, which were CA 19-9 negative,
stained positively for CA 242 (Table I). On the other hand,
two well to moderately differentiated and four poorly
differentiated or anaplastic carcinomas were negative for
CA 242, in spite of a positive CA 19-9 staining. Two CA 50-
negative well differentiated carcinomas were positive for
CA 242, whereas two well to moderately differentiated and
six poorly differentiated or anaplastic carcinomas were CA 50
positive but CA 242 negative (Table I). Benign and malignant
mucinous tumours stained for all three antigens. Serous cyst-
adenomas were positive only for CA 50, but were negative
for CA 242 and CA 19-9. Benign islet cell tumours were
always negative. In islet cell carcinomas occasional cells
stained for CA 242, but the number of positive cells was
smaller than for CA 50, whereas these tumours were negative
for CA 19-9.
Correlation between tissue staining and serum concentration of
CA 242
Serum was available in 23 of the patients with pancreatic
cancer. A value higher than 20 U ml-' was found in 65% of
these patients (Table II). There was no clearcut correlation
between the histological expression and the serum levels of
the antigens.
Discussion
Lindholm et al. (1983, 1985) have raised several antibodies to
colorectal carcinoma cell line COLO 205. Initially one of
them, the C 50 antibody, was more widely studied, and a
tumour marker test, CA 50, based on this antibody has been
developed (Holmgren et al., 1984). The antigenic epitope of
CA 50 is similar, although not identical, to that of tumour
marker CA19-9 (MAnsson et al., 1985; Nilsson et al., 1985).
Monoclonal antibody C 242 was raised against the same
carcinoma cell line as CA 50 (Lindholm et al., 1985). The
exact nature of the antigenic determinant of CA 242 is not
known, but it seems to be a sialylated carbohydrate structure
Table 11 CA 242 in tissue and serum of patients with pancreatic
cancer
CA 242
Patient
Specimens number Tissuea Serumb
Small, well to moderately I + + 126
differentiated ductal 2 + + 76
adenocarcinomas 3 + + 15
4 + 9
5 + 5
6 ++ 5
Large, well to moderately 7 + 1960
differentiated ductal 8 + + 690
adenocarcinomas 9 + 690
10 + 219
11 + 153
12 + 135
13 + 9
14 5
Poorly differentiated and 15 + + 670
anaplastic carcinomas 16 207
17 + 47
18 + 5
Cystadenocarcinomas 19 + + 2320
20 + 910
21 + 470
Islet cell carcinomas 22 + 24
23 - 5
aArbitrary scoring, wide or uniform distribution of CA 242 was
scored as + + , positivity ofonly a few glands or occasional cells as +
The intensity of the staining affected scoring only in borderline cases.
bConcentration in units ml- ', cut-off level 20 U ml '.
related to type I chain (O. Nilsson, personal communication).
Thus, chemically it would be closely related to CA 19-9 and
CA 50, which is further supported by the similarities in
immunohistochemical expression of these three markers. The
sensitivity of the CA 242 antigen to neuraminidase implies
that sialic acid is an essential part of the structure.
We have previously reported the tissue expression of
CA 19-9 and CA 50 in pancreatic lesions (Haglund et al.,
1986 a, b). The CA 242 antigen is, like CA 19-9 and CA 50,
easily demonstrated by immunoperoxidase technique in
formalin-fixed, paraffin-embedded specimens. Although
CA 242 is apparently a normal constituent of the human
pancreas, it was very weakly expressed in healthy tissue. On
the other hand, it was strongly expressed in most carcinomas,
and always much stronger than in adjacent normal pancreas.
In acute pancreatitis the expression was much stronger than
in normal pancreas and centro-acinar cells also stained,
which was not the case in normal pancreas or in chronic
pancreatitis. The staining of CA 242 resembled that of
CA 19-9, whereas the expression of CA 50 was stronger and
more widely distributed in benign pancreatic tissue than that
of CA 242 and CA 19-9. The serum levels of the three
tumour markers are low in healthy individuals (DelVillano et
al., 1983; Holmgren et al., 1984; Nilsson et al., 1988), yet the
tissue expression of CA 50 in normal pancreas is quite
strong. Therefore, it is postulated that these antigens are not
usually shed into the blood stream from normal pancreatic
tissue. In pancreatitis about 1/5 of the patients have slightly
elevated serum levels of CA 19-9 and CA 50 (Haglund et al.,
1986c, 1987), whereas, in a preliminary study, no elevated
levels of CA 242 have been found (Kuusela et al., submitted).
The differences in tissue and serum expression in pancreatitis
show that these three markers are distinctly different.
CA 19-9, being a sialylated Lewisa structure, cannot be
expressed by Lewis negative individuals. An interesting ques-
tion is whether CA 242, like CA 50 (Haglund et al., 1986b), is
expressed in Lewis negative specimens. Previously the expres-
sion of Lewisa and Lewisb in CA 19-9 negative specimens has
been reported (Haglund et al., 1986a). Five well to
moderately differentiated ductal adenocarcinomas, which
were negative for CA 19-9, stained positively for CA 242.
Three of these were Lewisb positive, one Lewisa and Lewisb
positive, and only one Lewis negative. Five other Lewis
negative specimens were both CA 19-9 and CA 242 negative.
Thus, it seems that Lewis negative individuals may express
CA 242 weakly. On the other hand, these were all poorly
differentiated or anaplastic carcinomas, which seldom and
weakly express CA 242. The expression of CA 242 in panc-
reatic carcinomas seems to be more dependent on the degree
of differentiation than the expression of CA 19-9 and CA 50
(Haglund et al., 1986a, b).
Although most carcinoma specimens were positive or
negative for all three antigens, 11 specimens stained for either
CA 242 or CA 19-9 and 10 specimens for either CA 242 or
CA 50. This also supports previous findings that the C 242
antibody detects a different antigenic determinant from the
19-9 and C 50 antibodies. Notably, no specimen was positive
for CA 242 but negative for both CA 19-9 and CA 50.
The expression of CA 242 correlates with the degree of
differentiation in the ductal carcinomas, being strongest in
well differentiated tumours. The findings are in concordance
with those for CA 19-9 and CA 50 (Haglund et al., 1986a, b;
Ichihara et al., 1988). The sequential change in antigenic
distribution from normal epithelium to poorly differentiated
and anaplastic carcinomas represents loss of polar distribu-
tion of membrane associated antigens, which has been des-
cribed in various gastrointestinal carcinomas (Ahnen et al.,
1982; Nagura et at., 1983; Ichihara et al., 1988) However,
the differences between the staining pattern in benign and
malignant pancreatic lesions are not clear enough to make
immunohistochemical staining of CA 242 useful in distin-
guishing between chronic pancreatitis and carcinoma. Similar
results have previously been reported for normal and neo-
plastic colon mucosa (Ouyang et al., 1987). The expression of
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rointestinal organs is still poorly known. However, due to the
strong expression in many pancreatic carcinomas, compared
to adjacent pancreatic tissue, C 242 might be useful for
immunolocalisation.
There was no correlation between the tissue expression and
the serum levels of CA 242, which is in confirmity with
previous findings for CA 19-9 and CA 50 (Haglund et al.,
1986a, b; Nishida et al., 1988). Many tissue positive car-
cinomas were associated with a normal or only slightly
elevated serum level of CA 242. On the other hand, high
serum values were seen in patients with a weakly or
moderately positive staining, and in one patient even in spite
of a negative tissue staining. This indicates that factors other
than antigen production in the tumour affect the serum
levels. These factors may include invasion, extent and
localisation of tumour spread as well as factors affecting the
metabolism and excretion of the antigen.
In clinical practice, CA 19-9 and CA 50 have been found
to be useful tumour markers in the diagnosis and follow-up
of gastrointestinal tumours, particularly pancreatic cancer
(Ritts et al., 1984; Jalanko et al., 1984; Haglund et al., 1986c,
1987). Both CA 19-9 and CA 50 are better tumour markers
in the diagnosis of pancreatic cancer than previously
available markers, e.g. CEA (Haglund et al., 1986a; Kuusela
et al., 1987). However, the disadvantage of these markers is
that elevated values are found also in association with certain
benign diseases, sometimes in chronic pancreatitis and
especially in benign extrahepatic biliary obstruction. In this
study we have shown that pancreatic carcinomas also
strongly express CA 242, an antigen closely related to, but
still different from, CA 50 and CA 19-9. This new tumour
associated antigen seems potentially useful as a tumour
marker in the diagnosis of pancreatic cancer. However, fur-
ther studies on the serum expression of CA 242 in patients
with pancreatic cancer and in relevant benign controls are
needed to evaluate whether the serum assay for CA 242,
alone or combined with other tests, has any advantages over
CA 19-9 and CA 50.
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